Citalopram: Clinical Evidence & Trials
Citalopram is a selective serotonin reuptake inhibitor (SSRI) used as a first-line treatment for depression, anxiety disorders, OCD, and PTSD.
SSRIs are first-line pharmacotherapy for depression and anxiety disorders with the strongest evidence base in psychiatry.
Evidence Strength
Level A (Strong) — multiple large RCTs and meta-analyses support efficacy for MDD, GAD, OCD, panic disorder, PTSD, and social anxiety disorder.
Key Clinical Trial Findings
- •Cipriani et al. (Lancet 2018) — largest antidepressant network meta-analysis (522 trials, 116,477 patients): all SSRIs more effective than placebo; NNT ≈ 7 for response
- •STAR*D trial — real-world effectiveness study: ~33% remission in initial SSRI treatment; sequential switching effective
- •NICE CG90 (updated 2022) — recommends SSRIs as first-line pharmacological treatment for moderate–severe depression
- •Cochrane reviews for anxiety disorders consistently show NNT 4–8 for response vs placebo
- •FDA approved for: OCD, panic disorder, PTSD, PMDD, social anxiety disorder (varies by specific SSRI)
Numbers Needed to Treat (NNT)
Depression: NNT ≈ 7 for response, NNT ≈ 9 for remission vs placebo. OCD: NNT ≈ 5 for ≥25% Y-BOCS reduction. Panic disorder: NNT ≈ 6 for panic-free status.
Guideline Recommendations
First-line by NICE (UK), APA (US), BAP, CANMAT, and WHO Essential Medicines List. Preferred over TCAs due to superior tolerability and safety in overdose.
Conditions Treated with Citalopram
Questions about your medication?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant medications.
Use AI Symptom Checker →